PubMed

Multicenter Clinical Performance Evaluation of Omadacycline Susceptibility Testing of Enterobacterales on VITEK 2 Systems.

PMID: 37162363 · 2023-05-10

E, d, i, t, h, , C, s, i, k, i, -, F, e, j, e, r, ;, , M, a, r, i, a, , T, r, a, c, z, e, w, s, k, i, ;, , G, a, r, y, , W, , P, r, o, c, o, p, ;, , T, h, o, m, a, s, , E, , D, a, v, i, s, ;, , M, e, r, e, d, i, t, h, , H, a, c, k, e, l, ;, , H, a, r, i, , P, , D, w, i, v, e, d, i, ;, , D, a, v, i, d, , H, , P, i, n, c, u, s

ЖурналJournal of clinical microbiology

Год2023-05-10

PMID37162363

Аннотация

We present the first performance evaluation results for omadacycline on the VITEK 2 and VITEK 2 Compact Systems (bioMérieux, Inc.). The trial was conducted at four external sites and one internal site. All sites were in the United States, geographically dispersed as follows: Indianapolis, IN; Schaumburg, IL; Wilsonville, OR; Cleveland, OH; and Hazelwood, MO. In this multisite study, omadacycline was tested against 858 Enterobacterales on the VITEK 2 antimicrobial susceptibility test (AST) Gram-n

Официальный источник

Открыть в PubMed →

Данные получены из PubMed / NCBI. Полный текст и наиболее актуальную информацию всегда смотрите в официальной записи.